• Is the Better Benchtop DNA Sequencer Losing the Marketing War?

    Aug 15, 2012, 11:30 AM by Michael Croft

    Forbes.com | According to an analyst at Macquarie Equities Research, in the battle of benchtop sequencers the Ion Torrent PGM is outselling the Illumina MiSeq by several hundred units, even though researchers tend to favor the MiSeq's technical performance. One reason might be that the PGM is $50,000 cheaper than the MiSeq. 

     

    Full story
  • How the FDA Stymies Progress -- and How to Get Around It

    Aug 13, 2012, 12:00 PM by Michael Croft

    The Skeptical Outsider GUEST COMMENTARY| Are cells taken from your body and then returned to it “drugs”? They are, according to a recent court ruling that granted the FDA an injunction against the developers of an adult stem cell therapy. And that doesn't sit well with Bill Frezza.

    Full story
  • Found in Translation: Where Do Cures Come From?

    Aug 13, 2012, 11:25 AM by Michael Croft
    The Guardian | In this opinion piece, Jenny Rohn asks, What's the best way of doing research? Throwing money at bright minds or trying to solve a particular problem? Or is there a third way? 
    Full story
  • Researchers Germinate Novel Approach to Big Bio Data

    Aug 10, 2012, 13:50 PM by Michael Croft
    Datanami | C. Titus Brown heads MSU’s lab for Genomics, Evolution, and Development, which recently undertook the task of researching large collections of metagenomics data. The project was so complex that Brown’s team had to fashion a solution to solve a specific problem.
    Full story
  • Eric Schadt: Why Biology Needs a Steve Jobs

    Aug 10, 2012, 08:35 AM by Michael Croft

    Nature Biotechnology | Eric Schadt, director of Mount Sinai's new Institute for Genomics and Multiscale Biology, discusses his vision to spend $100 million launching Mount Sinai to the forefront of the genomics revolution—and why he's enlisting Wall Street quants, user interface gurus and Facebook's former data whiz to do it.

    Full story
  • Nic Volker, Living on the Edge of Science

    Aug 9, 2012, 10:10 AM by Michael Croft

    JS Online | Two years after exome sequencing prompted a life-saving cord blood transplant, 7-year-old Wisconsinite Nic Volker is enjoying school, real food, good health and life in general. 

    Full story
  • Clinical Trial is Favorable for Microarray Prenatal Gene Test

    Aug 9, 2012, 08:40 AM by Michael Croft
    New York Times | The use of microarrays for prenatal testing to detect more genetic problems in a fetus than standard kayrotype testing could be headed toward wider use after encouraging results from an NIH-sponsored clinical trial of more than 4,000 pregnancies.  
    Full story
  • Physicians May Not Be Social, But They are Interactive

    Aug 9, 2012, 08:20 AM by Michael Croft
    Forbes.com | The desire to understand physician behavior, identify Key Opinion Leaders, and reach those influencers in a measured way is of extreme importance to pharmaceutical executives, writes Jim Golden in his latest blog.  
    Full story
  • CardioDx Wins Medicare OK of Molecular Test for Heart Disease

    Aug 8, 2012, 14:25 PM by Michael Croft
    Xconomy | After three years marketing a new genetic test that can tell when a patient’s chest pain is a sign of serious heart disease, CardioDX has taken a big step forward by persuading Palmetto GBA, the national contractor for Medicare, to reimburse the company for its Corus CAD test.
    Full story
  • Congratulations on Reaching the $1000 Genome

    Aug 6, 2012, 11:00 AM by Michael Croft
    PolITigenomics | For all intents and purposes, argues David Dooling, we have already achieved the $1,000 human genome -- compared to the $1 billion or spent on the first human genome, the difference between $1,000 and $5,000 is just a rounding error. "So, congratulations, we did it!"
    Full story
  • Quinten’s Savoir Faire Approach to Data Mining

    Aug 3, 2012, 10:55 AM by Michael Croft

    Bio-IT World | Quinten, a rapidly expanding French CRO, brings an innovative data-mining approach to much of the drug development pipeline – from early stage target identification to clinical trials and patient stratification. Here, Kevin Davies interviews Quinten CEO Alexandre Templier. 

    Full story
  • Drug Discovery Looks for Its Next Fix

    Aug 3, 2012, 10:30 AM by Michael Croft
    HPC Wire | Supercomputing shows great promise to improve the process of drug discovery, not only to find better, safer drugs, but also to weed out those compounds that would eventually fail during clinical trials. 
    Full story
  • Five Steps for Handling your Big Data Hoard

    Aug 3, 2012, 10:25 AM by Michael Croft
    Enterprise CIO Forum | Decades ago, valued data was handled in a very manual and individual manner. But the explosion of data sources has made most people hoarders, without a plan to leverage the value. 
    Full story
  • Russian Web Tycoon Launches World's Biggest Science Prize

    Jul 31, 2012, 10:55 AM by Michael Croft
    The Guardian | Yuri Milner, a Russian internet investor who quit his PhD in physics and made $1 billion investing in social networking firms such as Facebook, Twitter and Groupon, has launched a clutch of awards worth $3 million apiece to recognise advances in fundamental physics.
    Full story
  • 23andMe Seeks FDA Approval for Personal DNA Test

    Jul 30, 2012, 14:40 PM by Michael Croft
    Bloomberg Businessweek | Consumer genetics pioneer 23andMe has taken the first step towards seeking Food and Drug Administration approval of its personalized DNA test.  
    Full story
  • Sharp Dip in US Drug Approvals Forecast

    Jul 30, 2012, 11:50 AM by Michael Croft
    Pharma Times | The US Food and Drug Administration (FDA) will approve fewer novel drugs in 2012 than it did last year, as the industry faces a number of ongoing operational risks, according to a new report.
    Full story
  • A New Chapter for the Consumer Genetics Conference

    Jul 27, 2012, 09:35 AM by Michael Croft

    Bio-IT World | Asked what prompted her to launch The Consumer Genetics Conference (CGC) three years ago, together with her friend John Boyce, Meredith Salisbury says simply, “Insanity.” Coming to their senses, the duo have partnered with CHI to produce the 2012 conference, which will be held October 3-5, 2012. 

    Full story
  • Complete Genomics Bundles Ingenuity Variant Analysis software

    Jul 26, 2012, 17:05 PM by Michael Croft
    Bio-IT World | Complete Genomics announced that it will bundle Ingenuity Systems’ Variant Analysis application with its research whole genome sequencing services.
    Full story
  • John Reynders on the Role of R&D Information at AstraZeneca

    Jul 25, 2012, 02:30 AM by Michael Croft
    Bio-IT World | In his current role as head of R&D Information at AstraZeneca, John Reynders discusses the breadth of skills among his 400-strong team and the company’s commitment to innovation and long-range strategic planning. 
    Full story
  • Lasker Foundation Begins Search for Next President

    Jul 24, 2012, 14:55 PM by Michael Croft

    Bio-IT World | The Albert and Mary Lasker Foundation has embarked upon a global search for its next president to lead its operations, succeeding current chief Maria Freire, who is leaving this Fall. 

    Full story